Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT03614650
PHASE1/PHASE2
Immunotherapy Treating GI Cancer
Sponsor: Shenzhen Geno-Immune Medical Institute
View on ClinicalTrials.gov
Summary
The primary objectives are to evaluate the safety and efficacy of infusion of autologous gastro-intestinal (GI) cancer antigen-specific engineered immune effector cells (EIE).
Official title: Antigen-specific Engineered Immune Effector Cells (EIE) Against Gastro-Intestinal (GI) Cancer
Key Details
Gender
All
Age Range
1 Year - 80 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-07-01
Completion Date
2028-12-31
Last Updated
2026-06-16
Healthy Volunteers
No
Conditions
Interventions
BIOLOGICAL
engineered immune cells
Engineered immune effector cells (EIE)
Locations (1)
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China